Journal of Clinical Toxicology
Open Access
ISSN: 2161-0495
ISSN: 2161-0495
Li Yang, Yanwei He, Nana Xu, Bo Yu, Min Tang and Mishan Wu*
Objective: To evaluate efficacy and safety of WangBi Components (WBC) in the treatment of Rheumatoid Arthritis (RA) using systematic and meta-analysis technique.
Methods: Potentially eligible studies were found from PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), VIP Database for Chinese Technical Periodicals, Wanfang Database on Academic Institutions in China, Chinese Medical Journal Full-text Database, ClinicalTrials.gov and EBSCOhost by a search strategy including the terms "WangBi" and "rheumatoid arthritis" from inception to September 23, 2024. Eligible randomized controlled trials must consist of one group of treatment regimens containing WBC and another group without WBC. Two reviewers independently evaluated the quality of the included studies and extracted materials for bias risk assessment. Finally, Revman 5.4 was used for meta-analysis, and the publication bias was detected by Stata 15.
Results: Finally, 22 RCTs involving 2682 subjects were included; for RA, WBC can improve the overall effective rate, improve the Visual Analog Score (VAS), disease activity of 28 joints (DAS29), reduce CRP, ESR, TNF-α, Rheumatoid Factor (RF), CCP, number of swollen joints, number of painful joints, number of tender joints, duration of morning stiffness, grip strength of both hands and can improve even reduce adverse events. The Egger test for the number of joint tenderness indicated the existence of publication bias.
Conclusion: WBC can improve the symptoms and inflammation levels of patients with RA, but due to the low quality of RCTs, the conclusions should be interpreted with cation and still need to be revised or verified by highquality, large-sample, multicenter clinical trials.
Published Date: 2025-06-08; Received Date: 2024-11-12